Quantcast

Sangamo BioSciences Announces License Agreement With Pfizer for Zinc Finger Nucleases for Protein Production

December 22, 2008

RICHMOND, Calif., Dec. 22 /PRNewswire-FirstCall/ — Sangamo BioSciences,
Inc. (Nasdaq: SGMO), the leading developer of zinc finger DNA-binding proteins
(ZFPs), today announced an agreement to provide Pfizer Inc (NYSE: PFE) with a
worldwide, non-exclusive license for the use of certain ZFP Nuclease (ZFNs)
reagents to permanently eliminate the Glutamine Synthetase (GS) gene in
Chinese Hamster Ovary (CHO) cell lines and for the use of these ZFN-modified
cells for clinical and commercial production of therapeutic proteins. Under
the terms of the agreement Sangamo will receive an upfront payment of $3.0
million
from Pfizer for a fully paid license.

“Pfizer was an early adopter of Sangamo’s ZFN technology for CHO cell
engineering,” said Edward Lanphier, Sangamo’s president and CEO. “Our
colleagues at Pfizer have made fundamental contributions to establish the
breadth and utility of ZFNs in cell line engineering. We are very pleased to
establish this non-exclusive, commercial protein production license providing
Pfizer with the right to use ZFNs to eliminate the GS gene in CHO cells, a
widely used selection marker for the generation of cell lines used for the
production of recombinant protein pharmaceuticals and monoclonal antibodies.
Based upon our ability to design ZFNs to any gene, we believe that this is one
of many future agreements we may establish, applying our ZFN technology in the
commercial production of protein-based pharmaceuticals.”

“We are very pleased to enter into this commercial protein production
license agreement with Sangamo. Together we’ve used ZFNs to generate specific
GS knockouts in CHO cells to streamline the creation of mAb production cell
lines,” said David Brunner, Vice President, Bioprocess Research & Development,
Pfizer Global Biologics. “We have generated significant research and process
development data following application of the ZFN platform technology. ZFNs
can be used to eliminate genes and potentially improve culture performance or
the characteristics of therapeutic proteins being manufactured.”

“Prior to the development of ZFN technology, methods for gene disruption
were limited by their efficiency, time to completion, and the potential for
confounding, off-target effects,” said Philip Gregory, D.Phil., Sangamo’s Vice
President for Research. “We have demonstrated the power and broad
applicability of our ZFN technology in the engineering of living cells in
multiple publications in high-impact, peer-reviewed journals. Earlier this
year we published work describing a rapid, single-step approach to targeted
gene knockout in mammalian cells using ZFNs (Proc Natl Acad Sci U S A.
2008;105):5809-14). We have demonstrated that we can achieve a permanent,
heritable elimination of a gene giving a true knockout of that gene in a cell
and all of its progeny. Our ZFN process is simple, rapid and highly specific
and does not require marker genes or the permanent insertion of foreign DNA.
Moreover, this is not limited to a single gene in a cell; our ZFNs can be used
to generate a cell line in which multiple genes are selectively and
specifically eliminated. We have been working with scientists at Pfizer to
establish that this process is compatible with suspension growth in serum-free
and animal component-free synthetic media which is an important consideration
in human therapeutic protein manufacturing. Our work also confirms that ZFNs
are highly-specific; we have not observed any negative impact on cell growth,
protein production yield or product characteristics.”

Terms of the Agreement

Under this agreement, Sangamo will provide a worldwide, fully paid,
perpetual, royalty free, non-exclusive, license for the use of certain ZFN
reagents for the elimination of the GS gene in Pfizer’s CHO cell lines and to
use such ZFN-modified CHO cells for clinical and commercial production of
therapeutic protein products. Sangamo will receive an upfront payment of $3.0
million
from Pfizer which constitutes full and complete payment for the
license. The license may not be sublicensed although Pfizer may transfer any
GS ZFN-modified CHO cell line to a contract manufacturer solely for such
contract manufacturer to manufacture Pfizer’s therapeutic proteins for Pfizer.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and modification.
The most advanced ZFP Therapeutic(TM) development program is currently in
Phase 2 clinical trials for evaluation of safety and clinical effect in
patients with diabetic neuropathy and ALS. Other therapeutic development
programs are focused on HIV/AIDS, neuropathic pain, cancer, nerve regeneration
and monogenic diseases. Sangamo’s core competencies enable the engineering of
a class of DNA-binding proteins known as zinc finger DNA-binding proteins
(ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has
created ZFP transcription factors (ZFP TF(TM)) that can control gene
expression and, consequently, cell function. Sangamo is also developing
sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as
a treatment for a variety of monogenic diseases, such as X-linked SCID and
hemophilia, and for infectious diseases, such as HIV. Sangamo has established
strategic partnerships with companies outside of the human therapeutic space
including Dow AgroSciences, Sigma-Aldrich Corporation and several companies
applying its ZFP technology to enhance the production of protein
pharmaceuticals. For more information about Sangamo, visit the company’s web
site at http://www.sangamo.com/.

This press release may contain forward-looking statements based on
Pfizer’s and Sangamo’s current expectations. These forward-looking statements
include, without limitation, the application of the ZFN technology in the
engineering of living cells and absence of negative effects on ZFN engineered
cells. Actual results may differ materially from these forward-looking
statements due to a number of factors, including technological challenges,
ability of Sangamo and Pfizer to develop commercially viable products and
technological developments by our competitors. See the company’s SEC filings,
and in particular, the risk factors described in the company’s Annual Report
on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo
assumes no obligation to update the forward-looking information contained in
this press release.

SOURCE Sangamo BioSciences, Inc.


Source: newswire



comments powered by Disqus